X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   MYLAN
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
MYLAN
Dec-14
VENUS REMEDIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1434,055-   
Low Rs652,858-   
Sales per share (Unadj.) Rs324.21,388.2-  
Earnings per share (Unadj.) Rs6.4167.2-  
Cash flow per share (Unadj.) Rs40.6269.2-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs366.0690.1-  
Shares outstanding (eoy) m12.34378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x0.32.5 12.9%   
Avg P/E ratio x16.220.7 78.4%  
P/CF ratio (eoy) x2.612.8 19.9%  
Price / Book Value ratio x0.35.0 5.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,2821,307,810 0.1%   
No. of employees `0000.925.0 3.6%   
Total wages/salary Rs m2510-   
Avg. sales/employee Rs Th4,430.121,010.8 21.1%   
Avg. wages/employee Rs Th278.00-   
Avg. net profit/employee Rs Th87.62,531.1 3.5%   
INCOME DATA
Net Sales Rs m4,000525,269 0.8%  
Other income Rs m23-3,062 -0.7%   
Total revenues Rs m4,023522,207 0.8%   
Gross profit Rs m785130,637 0.6%  
Depreciation Rs m42238,579 1.1%   
Interest Rs m34422,657 1.5%   
Profit before tax Rs m4266,339 0.1%   
Minority Interest Rs m0-272 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-372,790 -1.3%   
Profit after tax Rs m7963,277 0.1%  
Gross profit margin %19.624.9 78.9%  
Effective tax rate %-87.94.2 -2,090.0%   
Net profit margin %2.012.0 16.4%  
BALANCE SHEET DATA
Current assets Rs m2,606461,781 0.6%   
Current liabilities Rs m1,980361,020 0.5%   
Net working cap to sales %15.619.2 81.6%  
Current ratio x1.31.3 102.9%  
Inventory Days Days12878 164.3%  
Debtors Days Days43107 40.2%  
Net fixed assets Rs m5,353121,519 4.4%   
Share capital Rs m12318,575 0.7%   
"Free" reserves Rs m4,3930-   
Net worth Rs m4,516261,110 1.7%   
Long term debt Rs m1,618390,073 0.4%   
Total assets Rs m8,2911,051,728 0.8%  
Interest coverage x1.13.9 28.6%   
Debt to equity ratio x0.41.5 24.0%  
Sales to assets ratio x0.50.5 96.6%   
Return on assets %5.18.2 62.4%  
Return on equity %1.824.2 7.2%  
Return on capital %6.313.6 46.2%  
Exports to sales %00-   
Imports to sales %18.40-   
Net fx Rs m-7360-   
CASH FLOW
From Operations Rs m99769,047 1.4%  
From Investments Rs m-461-54,452 0.8%  
From Financial Activity Rs m-571-18,194 3.1%  
Net Cashflow Rs m-35-3,599 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.04 Rs / USD

Compare VENUS REMEDIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: DISHMAN PHARMA  ALKEM LABORATORIES  TORRENT PHARMA  BIOCON LTD  GLENMARK PHARMA  



Today's Market

Sensex Trades Rangebound; Metal, Pharma Stocks Top Losers(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading below the dotted line.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 18, 2018 03:21 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS